Trevi Therapeutics to Participate in Upcoming March Investor Conferences

Rhea-AI Summary

Trevi Therapeutics (Nasdaq: TRVI), focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatments, has announced its participation in three major investor conferences this March.

The schedule includes:

• TD Cowen 45th Annual Health Care Conference (March 3-5) in Boston, featuring a corporate presentation on March 4 at 10:30 AM ET by CFO Lisa Delfini and CCO Farrell Simon
• Leerink Partners Global Healthcare Conference (March 10-12) in Miami, with a presentation on March 12 at 8:00 AM ET by CEO Jennifer Good and CDO James Cassella
• Leerink Partners Mountain Meeting (March 23-26) in Jackson Hole, with CFO Lisa Delfini representing

All events will feature corporate presentations available to in-person attendees.

News Market Reaction – TRVI

-0.22%

-0.22% Session move

In the trading session that priced this news, TRVI declined 0.22%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW HAVEN, Conn., Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in March.

TD Cowen 45^th Annual Health Care Conference
March 3-5, 2025, Boston, Massachusetts
Corporate Presentation: March 4, 10:30-11:00am ET
Trevi Representatives: Lisa Delfini, Chief Financial Officer, and Farrell Simon, Chief Commercial Officer
A Corporate presentation is available for in-person conference attendees.

Leerink Partners Global Healthcare Conference
March 10-12, 2025, Miami, Florida
Corporate Presentation: March 12, 8:00am ET
Trevi Representatives: Jennifer Good, President and CEO, and James Cassella, Chief Development Officer
A Corporate presentation is available for in-person conference attendees.

Leerink Partners Mountain Meeting
March 23-26, 2025, Jackson Hole, Wyoming
Trevi Representative: Lisa Delfini, Chief Financial Officer
A Corporate presentation is available for in-person conference attendees.

About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. 

Chronic cough is highly prevalent in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough, and any associated damage, may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. 

Refractory chronic cough affects approximately 2-3 million adults in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly disruptive disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them. There are also no approved therapies for RCC in the U.S. 

Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.

For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.

Investor Contact
Jonathan Carlson
Trevi Therapeutics, Inc.
(203) 654 3286
carlsonj@trevitherapeutics.com

Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-participate-in-upcoming-march-investor-conferences-302386266.html

SOURCE Trevi Therapeutics, Inc.

FAQ

What investor conferences will Trevi Therapeutics (TRVI) attend in March 2025?

TRVI will attend three conferences: TD Cowen Health Care Conference (Boston, March 3-5), Leerink Partners Global Healthcare Conference (Miami, March 10-12), and Leerink Partners Mountain Meeting (Wyoming, March 23-26).

When is Trevi Therapeutics (TRVI) presenting at the TD Cowen conference?

TRVI will present at the TD Cowen conference on March 4, 2025, from 10:30-11:00 AM ET in Boston.

What is Trevi Therapeutics (TRVI) currently developing?

TRVI is developing Haduvio™ (oral nalbuphine ER) for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Which Trevi Therapeutics executives will present at the Leerink Partners Global Healthcare Conference?

Jennifer Good (President and CEO) and James Cassella (Chief Development Officer) will present on March 12 at 8:00 AM ET.